{"": [138, 1934, 0], "1. Introduction": [1935, 4852, 0], "2.1. Study Design and Population": [4865, 6648, 0], "2.2. Reactogenicity": [6649, 7584, 0], "2.3. Immunogenicity": [7585, 8252, 0], "2.4. Statistical Methods": [8253, 9340, 0], "2. Methods": [4853, 9340, 1], "3.1. Participants": [9353, 10568, 0], "3.2. Adverse Drug Reactions": [10569, 12397, 0], "3.3. Immunogenicity": [12398, 13644, 0], "3.4. Correlation between Adverse Effects, Anti-RBD IgG, and Neutralizing Antibodies GMT": [13645, 14111, 0], "3.5. Factors Associated with Adverse Events following Vaccination Using Multivariate Logistic Regression Analysis": [14112, 14904, 0], "3. Results": [9341, 14904, 1], "Limitations": [19756, 20513, 0], "4. Discussion": [14905, 20513, 1]}